CN113861130A - 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用 - Google Patents
联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用 Download PDFInfo
- Publication number
- CN113861130A CN113861130A CN202111151928.6A CN202111151928A CN113861130A CN 113861130 A CN113861130 A CN 113861130A CN 202111151928 A CN202111151928 A CN 202111151928A CN 113861130 A CN113861130 A CN 113861130A
- Authority
- CN
- China
- Prior art keywords
- biphenyl
- derivative
- sulphathiadiazoles
- antitumor drugs
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 Biphenyl sulfanilamide thiadiazole derivative Chemical class 0.000 title claims abstract description 8
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 7
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 7
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000010290 biphenyl Nutrition 0.000 claims abstract description 12
- 239000004305 biphenyl Substances 0.000 claims abstract description 12
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims abstract 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 3
- 229940002612 prodrug Drugs 0.000 abstract description 2
- 239000000651 prodrug Substances 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- 239000012453 solvate Substances 0.000 abstract description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 22
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 102000008096 B7-H1 Antigen Human genes 0.000 description 11
- 108010074708 B7-H1 Antigen Proteins 0.000 description 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 11
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 7
- 230000004850 protein–protein interaction Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229910052693 Europium Inorganic materials 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- ATEAASNFYTUARU-UHFFFAOYSA-N 4-amino-n-(1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical class C1=CC(N)=CC=C1S(=O)(=O)NC1=NN=CS1 ATEAASNFYTUARU-UHFFFAOYSA-N 0.000 description 1
- DHARILAASAAGJJ-UHFFFAOYSA-N 4-benzylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1CC1=CC=CC=C1 DHARILAASAAGJJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005011 alkyl ether group Chemical group 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于药物化学技术领域，尤其涉及联苯磺胺噻二唑类衍生物和制备方法，及其作为PD1/PDL1抑制剂在抗肿瘤药物中的应用。本发明的提供一种通式(I)所示的新型联苯磺胺噻二唑类衍生物，及其几何异构体或其药学上可接受的盐、水合物、溶剂化物或前药。本发明通过实验显示，本课题组合成的联苯磺胺噻二唑类衍生物具有开发抗肿瘤药物的前景。
Description
技术领域
本发明属于药物化学技术领域，尤其涉及联苯磺胺噻二唑类衍生物和制备方法，及其作为PD1/PD-L1抑制剂在抗肿瘤药物中的应用。
背景技术
尽管我们希望免疫系统自动将癌细胞视为“异物”，但是由于肿瘤细胞独特广泛的变异特点，免疫系统和肿瘤之间经常达到平衡一肿瘤耐受，免疫检查点失调成为肿瘤耐受的主要原因之一。免疫检查点是一类免疫抑制性分子，可以调节免疫的强度和力度。由程序性细胞死亡蛋白1(PD-1)及其同源配体程序性死亡配体(PDLS)调控的信号通路在抗癌药物的开发中备受关注。PD1配体在肿瘤细胞中的过表达抑制机体免疫系统，防止免疫系统杀伤肿瘤细胞。肿瘤抗体治疗的基本思路之一是阻断PD1/PD-L1蛋白-蛋白相互作用(PPI)，从而激活T细胞抗肿瘤免疫反应，清除肿瘤细胞。肿瘤抗体治疗的基本思路之一是阻断PD1-PDL蛋白-蛋白相互作用(PPI)，从而激活T细胞抗肿瘤免疫反应，清除肿瘤细胞。肿瘤抗体治疗的基本思路之一是阻断PD1/PD-L1蛋白-蛋白相互作用(PPI)，从而激活T细胞抗肿瘤免疫反应，清除肿瘤细胞。研究发现，进展期黑色素瘤、细胞肺癌(NSCLC)、肾细胞癌(RCC)应用单克隆抗体阻断该通路引起了持久客观的反应，与传统治疗相比，患者生存期显著延长。
综上所述，研究新型的特异性更强的PD1/PD-L1抑制剂，对肿瘤药物患者的临床免疫治疗至关重要。
发明内容
本发明针对现有技术的不足，提供一种联苯磺胺噻二唑类衍生物；以及该衍生物的制备方法和其作为PD1/PD-L1抑制剂在抗肿瘤药物中的应用。
为实现上述目的，本发明采取的技术方案是：本发明的提供一种通式(I)所示的联苯磺胺噻二唑类衍生物，及其几何异构体或其药学上可接受的盐、水合物、溶剂化物或前药；
所述R1、R2或R3选自氢、卤素、C1-C6烷氧基、C1-C6烷基、C1-C6环烷基、烯烃基、炔烃基或芳香基。
优选的，所述R1或R2选自氢、卤素、C1-C6烷氧基或C1-C6烷基。
优选的，所述R3选自C1-C6烷基。
本发明通式(I)所示的联苯磺胺噻二唑类衍生物，选自：
本发明所述的“烷基”是指直链或支链的烷基，其中C1-C6基团是指该部分中具有1-6个碳原子，即基团包含1、2、3、4、5或6个碳原子。
本发明所述的“烷氧基”是指烷基醚基烷基，例如甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、异丁氧基、仲丁氧基和叔丁氧基等。
本发明所述的“卤素”是指氟、氯、溴或碘。
按照本发明的式I化合物，均可按照路线1的方法进行合成，由相应的起始原料4-取代苯基苯甲醛与甲基或乙基取代的磺胺噻二唑发生还原胺化反应得到目标化合物。合成路线路线1如下。
本发明所述的联苯磺胺噻二唑类衍生物可以作为PD1/PD-L1抑制剂，作为肿瘤患者的临床免疫治疗药物。
具体实施方式
下述实施例旨在阐述而不是限制本发明的范围。化合物的核磁共振氢谱用BrukerARX-400测定，质谱用Agilent 1100LC/MS测定；所用试剂均为分析纯或化学纯。
实施例1。
将4-苯基苯甲醛(0.50g,2.74mmol)和磺胺甲噻二唑(0.74g,2.74mmol)溶于1,2-二氯乙烷中，然后分批加入醋酸硼氢化钠(1.74g,8.23mmol)，继续室温反应28h，TLC检测反应完成。加入40mL水，30mL二氯甲烷萃取，饱和食盐水洗涤有机层，Na2SO4干燥过夜。滤除干燥剂，减压蒸除溶剂，残余物经硅胶柱层析纯化，得0.59g，收率49.26％。
1H-NMR(400MHz,DMSO-d6)δ13.65(s,1H),7.74(d,J＝7.3Hz,2H),7.69(d,J＝8.5Hz,2H),7.50–7.46(m,4H),7.43-7.40(m,3H),7.31(s,1H),7.14(d,J＝8.5Hz,2H),4.32(s,2H),2.47(s,3H).ESI-MS m/z:437.1[M+H]+.
实施例2。
1H-NMR(400MHz,DMSO-d6)δ13.66(s,1H),7.69(d,J＝8.5Hz,2H),7.47(d,J＝7.8Hz,2H),7.40(d,J＝7.6Hz,2H),7.33–7.30(m,3H),7.16-7.14(m,4H),4.30(s,2H),2.48(s,3H),2.35(s,3H).ESI-MS m/z:451.1[M+H]+.
实施例3。
1H-NMR(400MHz,DMSO-d6)δ13.64(s,1H),7.71-7.69(m,3H),7.47(d,J＝7.8Hz,2H),7.43-7.40(m,3H),7.34-7.31(m,3H),7.12(d,J＝8.8Hz,2H),4.34(s,2H),2.48(s,3H),2.34(s,3H).ESI-MS m/z:451.1[M+H]+.
实施例4。
1H-NMR(400MHz,DMSO-d6)δ13.68(s,1H),7.66(d,J＝8.0Hz,2H),7.52–7.49(m,4H),7.42(d,J＝8.5Hz,2H),7.31(s,1H),7.14–7.11(m,4H),4.31(s,2H),2.46(s,3H).ESI-MS m/z:455.2[M+H]+.
实施例5。
1H-NMR(400MHz,DMSO-d6)δ13.61(s,1H),7.75-7.71(m,2H),7.69(d,J＝8.5Hz,2H),7.49-7.46(m,3H),7.40(d,J＝8.5Hz,2H),7.32-7.28(m,2H),7.11(d,J＝8.0Hz,2H),4.30(s,2H),2.47(s,3H).ESI-MS m/z:455.2[M+H]+.
实施例6。
1H-NMR(400MHz,DMSO-d6)δ13.60(s,1H),7.79(d,J＝7.5Hz,1H),7.69(d,J＝8.5Hz,2H),7.50–7.45(m,4H),7.40(t,J＝7.4Hz,1H),7.32(s,1H),7.25(t,J＝7.8Hz,1H),7.18-7.14(m,3H),4.32(s,2H),2.47(s,3H).ESI-MS m/z:455.1[M+H]+.
实施例7。
1H-NMR(400MHz,DMSO-d6)δ13.64(s,1H),8.10(d,J＝8.5Hz,2H),7.66–7.61(m,4H),7.46(d,J＝8.0Hz,2H),7.40(d,J＝7.8Hz,2H),7.32(s,1H),7.12(d,J＝8.2Hz,2H),4.32(s,2H),2.48(s,3H).ESI-MS m/z:471.1[M+H]+.
实施例8。
1H-NMR(400MHz,DMSO-d6)δ13.64(s,1H),7.76-7.71(m,2H),7.70(d,J＝8.2Hz,2H),7.49-7.44(m,3H),7.40(d,J＝8.5Hz,2H),7.33-7.28(m,2H),7.12(d,J＝8.4Hz,2H),4.31(s,2H),2.82(q,J＝7.1Hz,2H),1.22(t,J＝7.2Hz,3H).ESI-MS m/z:469.1[M+H]+.
实施例9。
1H-NMR(400MHz,DMSO-d6)δ13.66(s,1H),7.64(d,J＝8.0Hz,2H),7.53–7.49(m,4H),7.42(d,J＝8.4Hz,2H),7.30(s,1H),7.15–7.10(m,4H),4.30(s,2H),2.81(q,J＝7.1Hz,2H),1.24(t,J＝7.1Hz,3H).ESI-MS m/z:469.1[M+H]+.
实施例10。
1H-NMR(400MHz,DMSO-d6)δ13.64(s,1H),7.64(d,J＝8.0Hz,2H),7.53–7.46(m,4H),7.40(d,J＝8.5Hz,2H),7.30(s,1H),7.12(d,J＝8.5Hz,2H),6.98(d,J＝8.4Hz,2H),4.30(s,2H),3.81(s,3H),2.82(q,J＝7.0Hz,2H),1.22(t,J＝7.2Hz,3H).ESI-MS m/z:481.1[M+H]+.
实施例11。
1H-NMR(400MHz,DMSO-d6)δ13.64(s,1H),7.78(d,J＝7.4Hz,1H),7.68(d,J＝8.2Hz,2H),7.51–7.46(m,4H),7.41(t,J＝8.4Hz,1H),7.34(s,1H),7.23(t,J＝7.4Hz,1H),7.18-7.14(m,3H),4.31(s,2H),2.80(q,J＝7.2Hz,2H),1.20(t,J＝7.4Hz,3H).ESI-MS m/z:469.1[M+H]+.
一、HTRF均相时间分辨荧光技术。
测试原理：Cisbio公司开发的HTRF PD-1/PD-L1 binding assay kit试剂盒，PD-1/PD-L1结合测定旨在测量PD-1和PD-L 1蛋白之间的相互作用。通过使用抗Tag1-Europium(HTRF供体)和抗Tag2-XL665(HTRF受体)来检测Tag1-PD-L1和Tag2-PD-1之间的相互作用。当供体抗体和受体抗体由于PD-L1和PD-1的的紧密结合而接近时，供体抗体的激发引发朝向受体抗体的荧光共振能量转移((FRET)，后者又在665nm处特异性发射。该特定信号与PD-1/PD-L1相互作用的程度成正比。因此阻断PD-1/PD-L 1相互作用的化合物将导致HTRF信号的减弱。
测试方法：按照说明书操作，对本发明所述的化合物测试对PD-1/PD-L1的抑制效果。在384孔板中预设给药组、对照组和阴性对照组，每组三个复孔。依次向每孔中加入4μLTag1-PD-L1工作液、4μL Tag1-PD-1工作液，并吹打均匀；接着向每孔中加入2μL的化合物稀释液，混合均匀室温孵育15min后，向每孔中依次加入Anti-Tag1-Europium和Anti-Tag2-XL665，封膜避光孵育2小时，使用Tecan酶标仪读取荧光值(Ex:320nM；Em:620和665nM)，然后计算抑制率及拟合IC50，见表1。
表1化合物测试对PD-1/PD-L1的抑制活性(IC50)。
| 实施例 | IC<sub>50</sub>(μM) |
| 实施例1 | 5.6 |
| 实施例2 | 14.6 |
| 实施例3 | 24.9 |
| 实施例4 | 1.9 |
| 实施例5 | 0.26 |
| 实施例6 | 0.37 |
| 实施例7 | 2.7 |
| 实施例8 | 0.46 |
| 实施例9 | 0.68 |
| 实施例10 | 0.84 |
| 实施例11 | 0.95 |
采用HTRF(均相时间分辨荧光)技术标准操作程序测定本发明所述的一种联苯磺胺噻二唑类衍生物对PD-1/PD-L1的抑制效果，结果显示该化合物对PD-1/PD-L1具有明显的抑制作用。
Claims (5)
1.联苯磺胺噻二唑类衍生物，其特征在于，所述的衍生物结构式如下：
其中，所述R1、R2或R3选自氢、卤素、C1-C6烷氧基、C1-C6烷基、C1-C6环烷基、烯烃基、炔烃基或芳香基。
2.如权利要求1所述的联苯磺胺噻二唑类衍生物，其特征在于，所述R1或R2选自氢、卤素、C1-C6烷氧基或C1-C6烷基。
3.如权利要求1所述的联苯磺胺噻二唑类衍生物，其特征在于，所述R3选自C1-C6烷基。
4.如权利要求1所述的联苯磺胺噻二唑类衍生物，其特征在于，所述的衍生物选自：
5.如权利要求1-4任一所述的联苯磺胺噻二唑类衍生物作为PD1/PDL1抑制剂，作为肿瘤患者的临床免疫治疗药物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111151928.6A CN113861130A (zh) | 2021-09-29 | 2021-09-29 | 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111151928.6A CN113861130A (zh) | 2021-09-29 | 2021-09-29 | 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113861130A true CN113861130A (zh) | 2021-12-31 |
Family
ID=78992786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111151928.6A Withdrawn CN113861130A (zh) | 2021-09-29 | 2021-09-29 | 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113861130A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009129267A2 (en) * | 2008-04-14 | 2009-10-22 | The Board Of Regents Of The University Of Texas System | Small molecule inhibitors of the pleckstrin homology domain and methods for using same |
| CN103664878A (zh) * | 2012-09-12 | 2014-03-26 | 山东亨利医药科技有限责任公司 | 杂芳环及其衍生物类酪氨酸激酶抑制剂 |
| WO2015054662A1 (en) * | 2013-10-10 | 2015-04-16 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors |
| WO2016210296A1 (en) * | 2015-06-26 | 2016-12-29 | Dana-Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
| CN110325531A (zh) * | 2016-12-09 | 2019-10-11 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
-
2021
- 2021-09-29 CN CN202111151928.6A patent/CN113861130A/zh not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009129267A2 (en) * | 2008-04-14 | 2009-10-22 | The Board Of Regents Of The University Of Texas System | Small molecule inhibitors of the pleckstrin homology domain and methods for using same |
| CN103664878A (zh) * | 2012-09-12 | 2014-03-26 | 山东亨利医药科技有限责任公司 | 杂芳环及其衍生物类酪氨酸激酶抑制剂 |
| WO2015054662A1 (en) * | 2013-10-10 | 2015-04-16 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors |
| WO2016210296A1 (en) * | 2015-06-26 | 2016-12-29 | Dana-Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
| CN110325531A (zh) * | 2016-12-09 | 2019-10-11 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Synthesis, molecular modeling and biological evaluation of chalcone thiosemicarbazide derivatives as novel anticancer agents | |
| Amin et al. | Synthesis and molecular docking study of new benzofuran and furo [3, 2-g] chromone-based cytotoxic agents against breast cancer and p38α MAP kinase inhibitors | |
| Batran et al. | New coumarin derivatives as anti‐breast and anti‐cervical cancer agents targeting VEGFR‐2 and p38α MAPK | |
| Yuan et al. | Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy | |
| Ma et al. | Virtual screening and optimization of Type II inhibitors of JAK2 from a natural product library | |
| Li et al. | Development of photocontrolled BRD4 PROTACs for tongue squamous cell carcinoma (TSCC) | |
| Xu et al. | The synthesis and anti-proliferative effects of β-elemene derivatives with mTOR inhibition activity | |
| López‐Ramos et al. | New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights | |
| Elsayed et al. | Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors | |
| Ibrahim et al. | Synthesis and biological evaluation of some novel thiobenzimidazole derivatives as anti-renal cancer agents through inhibition of c-MET kinase | |
| Liu et al. | Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines | |
| Guo et al. | Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors | |
| Xu et al. | New modification strategy of matrine as Hsp90 inhibitors based on its specific L conformation for cancer treatment | |
| WO2011041655A1 (en) | Quinazolin-4-amine derivatives; and methods of use | |
| Kaur et al. | Design, synthesis, in vitro and in silico evaluation of indole-based tetrazole derivatives as putative anti-breast cancer agents | |
| Liu et al. | Identification and characterization of MAM03055A: A novel bivalent sigma-2 receptor/TMEM97 ligand with cytotoxic activity | |
| WO2021176428A1 (en) | Phenanthroline, carbazole and flavylium based cyanines and compositions and methods of making and using the same | |
| CN113861130A (zh) | 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用 | |
| CN110407806B (zh) | 甲酰胺类化合物、其制备方法及其应用 | |
| Pagano et al. | Identification of a novel extracellular inhibitor of FGF2/FGFR signaling axis by combined virtual screening and NMR spectroscopy approach | |
| Wang et al. | Synthesis and vasorelaxation evaluation of novel biphenyl–furocoumarin derivatives | |
| El-Kardocy et al. | Aryl azide-sulfonamide hybrids induce cellular apoptosis: synthesis and preliminary screening of their cytotoxicity in human HCT116 and A549 cancer cell lines | |
| CN105348268B (zh) | 取代的咔唑-吲哚磺酸盐衍生物及其制备方法和用途 | |
| RU2570907C2 (ru) | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. | |
| CN113698357A (zh) | 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20211231 |